carboplatin + cyclophosphamide + melphalan + paclitaxel + thiotepa

This is a combination of five chemotherapeutic agents used in sequential high-dose chemotherapy regimens for advanced cancers such as metastatic breast cancer. The regimen typically involves three separate cycles of high-dose therapy with peripheral blood progenitor support and G-CSF. The first cycle is usually paclitaxel, the second melphalan, and the third a combination of cyclophosphamide, thiotepa, and carboplatin (CTCb). This approach aims to maximize tumor cell kill by using different mechanisms of action in sequence. The regimen has shown feasibility in clinical trials for women with metastatic breast cancer who have at least a partial response to induction chemotherapy[1][2][3].

Other names

CTCb regimen (when referring to cyclophosphamide, thiotepa, carboplatin; note that this does not include melphalan or paclitaxel)sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin